NewGenIvf Group (NIVF) director exercises stock options, holds 56,890 shares

Rhea-AI Filing Summary

NewGenIvf Group Ltd director Fong Hei Yue Tina exercised stock options to acquire additional shares in the company. She exercised vested options to receive 56,851 Class B Ordinary Shares at an exercise price of $0.0001 per share under the issuer's 2024 Share Incentive Plan.

Following this option exercise, she directly holds 56,890 Class B Ordinary Shares. The options were granted under an employee share option agreement dated 4 May 2026, were accelerated by the independent directors on 26 May 2026, and were exercised on 4 June 2026. This is a compensation-related derivative exercise, not an open-market purchase or sale.

Insights

Equity compensation analyst

Director exercised stock options to acquire shares; routine compensation event with no open-market sale.

Director Fong Hei Yue Tina exercised vested stock options to acquire 56,851 Class B Ordinary Shares of NewGenIvf Group Ltd at $0.0001 per share. The options were granted under the 2024 Share Incentive Plan via an employee share option agreement dated 4 May 2026.

The independent directors accelerated these options on 26 May 2026, and they were exercised on 4 June 2026. After the exercise, she holds 56,890 Class B Ordinary Shares directly. There is no accompanying sale or tax-withholding disposition, indicating an exercise-and-hold pattern based on the information provided.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Fong Hei Yue Tina

Role null

Type	Security	Shares	Price	Value
Exercise	Class B Ordinary Shares	56,851	$0.0001	$5.69

Holdings After Transaction: Class B Ordinary Shares — 56,890 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired via option exercise: 56,851 shares Exercise price: $0.0001 per share Shares held after transaction: 56,890 shares +5 more

8 metrics

Shares acquired via option exercise 56,851 shares Class B Ordinary Shares acquired through option exercise on 4 June 2026

Exercise price $0.0001 per share Exercise price for Class B Ordinary Shares under stock options

Shares held after transaction 56,890 shares Total Class B Ordinary Shares directly held following option exercise

Transaction code M Exercise or conversion of derivative security reported on Form 4

Plan name 2024 Share Incentive Plan Equity compensation plan under which options were granted

Option agreement date 4 May 2026 Date of employee share option agreement with the reporting person

Acceleration date 26 May 2026 Date independent directors accelerated the options

Exercise date 4 June 2026 Date options were exercised to acquire Class B shares

Key Terms

Class B Ordinary Shares, stock options, 2024 Share Incentive Plan, employee share option agreement, +2 more

6 terms

Class B Ordinary Shares financial

"The Class B Ordinary Shares were acquired through the exercise of vested stock options"

Class B ordinary shares are a type of ownership stake in a company that typically come with different voting rights or privileges compared to other share classes. For investors, they represent a way to hold part of the company’s value and influence its decisions, often with fewer voting rights than Class A shares. Understanding these shares helps investors assess their level of control and potential returns within a company.

stock options financial

"The Class B Ordinary Shares were acquired through the exercise of vested stock options ("Options")."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

2024 Share Incentive Plan financial

"The Options were granted pursuant to the Issuer's 2024 Share Incentive Plan"

employee share option agreement financial

"the employee share option agreement, dated 4 May 2026, between the Issuer and the Reporting Person"

independent directors financial

"The options were accelerated by resolution of the independent directors of the Board of Directors"

Members of a company’s board who do not have significant business, family, or financial ties to the company and are not part of its management; they are chosen to provide impartial oversight of strategy, financial reporting, executive pay and risk. They matter to investors because independent directors act like an objective referee, helping ensure decisions favor shareholders’ long-term interests rather than insiders, which can strengthen trust and reduce the chance of mismanagement or conflicts of interest.

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fong Hei Yue Tina

(Last) (First) (Middle)

C/O 1/F, PIER 2, CENTRAL

(Street)

HONG KONG

(City) (State) (Zip)

HONG KONG

(Country)

2. Issuer Name and Ticker or Trading Symbol
NewGenIvf Group Ltd [ NIVF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class B Ordinary Shares	06/04/2026		M		56,851	A(1)	$0.0001	56,890	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Class B Ordinary Shares were acquired through the exercise of vested stock options ("Options"). The Options were granted pursuant to the Issuer's 2024 Share Incentive Plan and the employee share option agreement, dated 4 May 2026, between the Issuer and the Reporting Person (the "Option Agreement"). The options were accelerated by resolution of the independent directors of the Board of Directors on 26 May 2026, and were exercised by the Reporting Person on 4 June 2026.

	/s/ Hei Yue Tina Fong	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did NewGenIvf Group Ltd (NIVF) report for Fong Hei Yue Tina?

NewGenIvf Group Ltd reported that director Fong Hei Yue Tina exercised stock options to acquire 56,851 Class B Ordinary Shares. The options were exercised at $0.0001 per share under the company’s 2024 Share Incentive Plan and an employee share option agreement dated 4 May 2026.

Did the NewGenIvf (NIVF) director buy or sell shares on the open market?

The director did not trade on the open market; she exercised vested stock options to acquire shares. The Form 4 shows an option exercise at $0.0001 per share, categorized as a derivative exercise/conversion rather than an open-market purchase or sale.

How many NewGenIvf (NIVF) shares does Fong Hei Yue Tina hold after this transaction?

After exercising her options, Fong Hei Yue Tina directly holds 56,890 Class B Ordinary Shares. This total reflects the addition of 56,851 shares from the option exercise, with the balance representing shares she held before this transaction according to the Form 4 data.

What is the exercise price of the stock options in this NewGenIvf (NIVF) Form 4?

The stock options were exercised at an exercise price of $0.0001 per Class B Ordinary Share. This very low exercise price is typical of employee options granted as part of equity compensation under the company’s 2024 Share Incentive Plan and option agreement.

Under which plan were the NewGenIvf (NIVF) options granted to the director?

The options were granted pursuant to NewGenIvf Group Ltd’s 2024 Share Incentive Plan. They are governed by an employee share option agreement dated 4 May 2026 between the company and the reporting person, as described in the Form 4 footnote.

Were the NewGenIvf (NIVF) director’s stock options accelerated before exercise?

Yes. The footnote explains that the options were accelerated by resolution of the independent directors of the Board of Directors on 26 May 2026. After this acceleration, the reporting person exercised the options on 4 June 2026 to acquire Class B Ordinary Shares.